Ads
related to: parkinson's disease trial results explained mayo clinic treatment resistant depression
Search results
Results From The WOW.Com Content Network
Some people who are diagnosed with treatment-resistant depression may have an underlying undiagnosed health condition that is causing or contributing to their depression. Endocrine disorders like hypothyroidism , Cushing's disease , and Addison's disease are among the most commonly identified as contributing to depression .
Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). [8] In Parkinson's disease it may be used alone or together with levodopa. [8] It is taken by mouth. [8] Pramipexole is a dopamine agonist of the non-ergoline class. [8]
The research in Parkinson's disease (also known as clinical trials, medical research, research studies, or clinical studies) refers to any study intended to help answer questions about etiology, diagnostic approaches or new treatments of Parkinson's disease (PD) by studying their effects on human subjects.
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
Vagus nerve stimulation therapy improved the symptoms of treatment-resistant depression for nearly 500 participants in a major clinical trial.
Newer MAOIs such as selegiline (typically used in the treatment of Parkinson's disease) and the reversible MAOI moclobemide provide a safer alternative [19] and are now sometimes used as first-line therapy. Pargyline is a non-selective MAOI that was previously used as an antihypertensive agent to treat hypertension (high blood pressure). [21] [22]